• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Chapman Christopher C JR

    4/21/21 4:49:03 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AKER alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Chapman Christopher C JR

    (Last) (First) (Middle)
    1185 AVENUE OF THE AMERICAS, 3RD FLOOR

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/16/2021
    3. Issuer Name and Ticker or Trading Symbol
    MyMD Pharmaceuticals, Inc. [ MYMD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, Chief Med. Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Chris Chapman 04/21/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AKER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKER

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKER
    SEC Filings

    View All

    SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)

    S-3/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

    4/28/21 5:25:54 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

    4/21/21 9:56:36 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akers Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Akers Biosciences, Inc. (0001321834) (Filer)

    4/16/21 4:00:32 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock

    3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/26/21 6:05:40 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by EAGLE CRAIG

    4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/22/21 9:29:07 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by EAGLE CRAIG

    3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/22/21 9:27:15 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

    Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol "MYMD" Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1 Recently announced plans to initiate Phase 2 trial Akers Biosciences, Inc. ("Akers") (NASDAQ:AKER) and MyMD Pharmaceuticals, Inc. ("MYMD") today announced that at Akers' special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents fr

    4/16/21 12:30:00 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial

    Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. In a finding published in JAMA Network Open on 3/12/21, it was found that 52% of individuals who had COVID-19 had an associa

    4/13/21 9:00:00 AM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board

    Chaired by Katharine Whartenby, Ph.D., members include experts in molecular medicine, aging, pathology and oncology Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. "Each member of our Scientific Adviso

    4/12/21 9:00:00 AM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Akers Biosciences, Inc. (0001321834) (Subject)

    2/22/21 9:56:10 AM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed

    SC 13G - Akers Biosciences, Inc. (0001321834) (Subject)

    2/18/21 2:22:29 PM ET
    $AKER
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care